Danish hearing healthcare company Demant reports a sharp increase in revenue in the third quarter, driven by strong organic growth in Hearing Aids and the acquisition of German company KIND. The figures are in line with the preliminary announcement made on October 9.
Net revenue rose 21,5 percent to 6 624 million Danish kroner (5 454). Organic sales growth was 11 percent. Acquisitions contributed 10 percent and currency effects 1 percent.
The Hearing Aids business area increased external revenue by 17 percent to 2 747 million Danish kroner (2 350). Organic growth was 17 percent, primarily driven by the launch of the Oticon Reveal hearing aid.
Hearing Care increased revenue by 29 percent to 3 278 million Danish kroner (2 537), with organic growth of 6 percent. The acquisition of KIND accounted for most of the acquisition-driven growth.
Diagnostics increased revenue by 6 percent to 599 million Danish kroner (567). Organic growth was 4 percent.
The company states that operating profit, EBIT before special items, improved significantly compared with the corresponding quarter of the previous year. No exact earnings figure is reported in the interim report.
CEO Søren Nielsen highlights that the successful launch of Oticon Reveal has strengthened the product portfolio and contributed to significant sales growth. Hearing Care and Diagnostics also developed positively.
Demant maintains the guidance raised on October 9. The company expects organic growth of 7–8 percent for the full year 2026 and EBIT before special items of 4 700–5 000 million Danish kroner.
The company has also resumed its share buybacks and expects repurchases of at least 3 billion Danish kroner through the end of 2027. The target of a leverage multiple of 2,0–2,5 at the end of 2027 is reiterated.
Key figures, DKK millionQ3 2026Q3 2025ChangeRevenue6 6245 454+21,5%Organic growth11%––Hearing Aids, external revenue2 7472 350+16,9%Hearing Care, revenue3 2782 537+29,2%Diagnostics, revenue599567+5,6%
